Publications by authors named "Barbara Botto"

Claim this Profile
O
Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis.
Anna Dodero, Giusy Ceparano, Beatrice Casadei, Piera Angelillo, Stefania Bramanti, Barbara Botto

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial.
Emanuele Zucca, Luca Ceriani, Giovannino Ciccone, Alice Di Rocco, Maria Cristina Pirosa, Barbara Botto

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Luca Legato, Matteo Bisio, Filippo Fasano, Corrado Benevolo Savelli, Carolina Secreto, Barbara Botto

Methods Protoc· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Copanlisib in combination with rituximab and bendamustine for transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma patients: Results from the phase II multicentre FIL Copa-BR trial from Fondazione Italiana Linfomi (FIL).
Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, Luigi Marcheselli, Samantha Deianira Dattoli, Barbara Botto

Br J Haematol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, LYSA, and Turkish Lymphoma Group.
Carmen Martínez, Irma Khvedelidze, Mathilde Fekom, Benedicte Deau Fischer, Amira Marouf, Barbara Botto

Bone Marrow Transplant· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Effectiveness of R-miniCOMP Versus R-miniCHOP in Older Non-Fit Patients With Diffuse Large B-Cell Lymphoma: Insights From a "Fondazione Italiana Linfomi" Cohort Study.
Alberto Bavieri, Sara Veronica Usai, Michele Merli, Alice Di Rocco, Federica Cavallo, Barbara Botto

Hematol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose therapy followed by autologous stem cell transplantation emerges as the preferred salvage therapy in patients with limited-stage Hodgkin lymphoma progressing/relapsing after initial therapy: A subset analysis of the EORTC/LYSA/FIL H10 trial.
Gotti Manuel, Yana Stepanishyna, Tetiana Skrypets, Luigi Marcheselli, Caterina Cristinelli, Barbara Botto

Hemasphere· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Efficacy and toxicity of brexucabtagene autoleucel in the treatment of high-risk mantle cell lymphoma: description of a clinical case].
Mattia Novo, Corrado Benevolo Savelli, Barbara Botto, Roberto Freilone

Recenti Prog Med· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients.
Rita Tavarozzi, Simone Ferrero, Andrea Evangelista, Elisa Genuardi, Daniela Drandi, Barbara Botto

Hemasphere· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.
Federico Stella, Annalisa Chiappella, Martina Magni, Francesca Bonifazi, Chiara De Philippis, Barbara Botto

Br J Haematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results.
Maurizio Martelli, Luca Ceriani, Giovannino Ciccone, Umberto Ricardi, Iryna Kriachok, Barbara Botto

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific Antibodies for Lymphoid Malignancy Treatment.
Matteo Bisio, Luca Legato, Filippo Fasano, Corrado Benevolo Savelli, Carola Boccomini, Barbara Botto

Cancers (Basel)· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas.
Federico Stella, Annalisa Chiappella, Beatrice Casadei, Stefania Bramanti, Silva Ljevar, Barbara Botto

Blood Cancer Discov· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study.
Irene Dogliotti, Veronica Peri, Michele Clerico, Francesco Vassallo, Davide Musto, Barbara Botto

Cancer Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice.
Corrado Benevolo Savelli, Matteo Bisio, Luca Legato, Filippo Fasano, Elisa Santambrogio, Barbara Botto

Cancers (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma.
Annarita Conconi, Annalisa Chiappella, Andrés J M Ferreri, Anastasios Stathis, Barbara Botto

Blood Adv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.
Corrado Benevolo Savelli, Michele Clerico, Barbara Botto, Carolina Secreto, Federica Cavallo

Cancers (Basel)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL.
Maria Chiara Tisi, Riccardo Moia, Caterina Patti, Andrea Evangelista, Simone Ferrero, Barbara Botto

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma.
Annalisa Arcari, Lugi Rigacci, Alessandra Tucci, Benedetta Puccini, Sara Veronica Usai, Barbara Botto

Blood Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL).
Alessandra Tucci, Francesco Merli, Alberto Fabbri, Luigi Marcheselli, Chiara Pagani, Barbara Botto

Haematologica· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Manuel Gotti, Roberta Sciarra, Alessandro Pulsoni, Francesco Merli, Stefano Luminari, Barbara Botto

Hemasphere· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The elderly prognostic index predicts early mortality in older patients with diffuse large B-cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi.
Emanuele Cencini, Alessandra Tucci, Benedetta Puccini, Federica Cavallo, Stefano Luminari, Barbara Botto

Hematol Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
Marina Moretti, Anna Marina Liberati, Luigi Rigacci, Benedetta Puccini, Alessandro Pulsoni, Barbara Botto

Clin Lymphoma Myeloma Leuk· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
Fulvio Massaro, Vincenzo Pavone, Piero Maria Stefani, Barbara Botto, Alessandro Pulsoni

Hematol Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience.
Michele Clerico, Irene Dogliotti, Paola Ghione, Vittorio Ruggero Zilioli, Francesco Merli, Barbara Botto

J Pers Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis